Free Trial

Achieve Life Sciences Q2 2024 Earnings Report

Achieve Life Sciences logo
$2.78 -0.12 (-4.14%)
As of 03/28/2025 04:00 PM Eastern

Achieve Life Sciences EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.22
Beat/Miss
Missed by -$0.03
One Year Ago EPS
-$0.43

Achieve Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Achieve Life Sciences Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Remove Ads

Achieve Life Sciences Earnings Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Achieve Life Sciences, Inc. (ACHV): A Bull Case Theory
ACHV: 2Q:25 NDA Submission
See More Achieve Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Achieve Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Achieve Life Sciences and other key companies, straight to your email.

About Achieve Life Sciences

Achieve Life Sciences (NASDAQ:ACHV), a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

View Achieve Life Sciences Profile

More Earnings Resources from MarketBeat